iloperidone Side Effects
Also known as: Fanapt
Analysis of 1,388 adverse event reports submitted to the FDA from 2009 to 2025.
Total Reports
1,388
Death-Related
59
4.3% of reports
Hospitalizations
216
15.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 59 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 26 |
| PULMONARY EMBOLISM | 7 |
| COMPLETED SUICIDE | 5 |
| COMA | 4 |
| PNEUMONIA | 4 |
| ROAD TRAFFIC ACCIDENT | 4 |
| SUDDEN DEATH | 4 |
| TACHYCARDIA | 4 |
| BRAIN DEATH | 3 |
| CARDIAC ARREST | 3 |
| PRIAPISM | 3 |
| ARRHYTHMIA | 2 |
| DIZZINESS | 2 |
| HERPES ZOSTER | 2 |
| HYPOTENSION | 2 |
| NEOPLASM MALIGNANT | 2 |
| RESPIRATORY ARREST | 2 |
| SUDDEN CARDIAC DEATH | 2 |
| SUICIDAL IDEATION | 2 |
| WEIGHT INCREASED | 2 |
Reactions in Hospitalization Reports
Top reactions in 216 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 15 |
| WEIGHT INCREASED | 15 |
| ASTHENIA | 13 |
| DIZZINESS | 13 |
| DYSPNOEA | 13 |
| TACHYCARDIA | 13 |
| ANXIETY | 12 |
| HEADACHE | 9 |
| PRIAPISM | 9 |
| PSYCHOTIC DISORDER | 9 |
| SYNCOPE | 9 |
| CONFUSIONAL STATE | 8 |
| HYPOTENSION | 8 |
| INSOMNIA | 8 |
| NAUSEA | 8 |
| SKIN DISCOLOURATION | 8 |
| SPEECH DISORDER | 8 |
| VEIN DISCOLOURATION | 8 |
| ABNORMAL BEHAVIOUR | 7 |
| ANGIOEDEMA | 7 |
Nearby — Related Medications
What the FAERS Data Reveals About iloperidone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,388 voluntary reports linked to iloperidone and its brand equivalents (Fanapt), spanning 2009 through 2025. Of those, 59 (4.3%) listed death as an outcome and 216 (15.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 51% were female and 49% male; age distribution skews toward 18-44, with 327 reports in that bracket. The single most reported reaction is drug ineffective with 107 submissions, followed by dizziness and insomnia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.